The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy

Pietro Ferrara, Antonio Gatto, Valeria Blasi, Federica Di Ruscio, Domenica Immacolata Battaglia

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

Background: Valproic acid (VPA) is an antiepileptic drug, used for focal and generalized seizure. VPA treatment resulted in significant weight gain but there are no systematic data about the prevalence of this side effect. The aim of the study is to evaluate the weight gain of a paediatric population with epilepsy. Methods: We enrolled 38 patients, 17 female and 21 male with a mean age of 8.2±4.4 years. We evaluated data about height, weight and BMI at beginning of treatment and at 24, 36 and 48 months of follow-up. Results: There is a statistical significant difference between the percentile value of weight and BMI at baseline and at 36 and 48 months of follow-up (P value <0.01) but there isn't statistical significant difference between the percentile value of height (P value 0.22 and 0.18). Conclusions: We believe that a nutritional support should be guaranteed to the pediatric patients with epilepsy that begin the VPA therapy.
Lingua originaleEnglish
pagine (da-a)408-411
RivistaMinerva Pediatrica
Volume74
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • antiepilectic drugs
  • children
  • epilepsy

Fingerprint

Entra nei temi di ricerca di 'The impact of valproic acid treatment on weight gain in pediatric patients with epilepsy'. Insieme formano una fingerprint unica.

Cita questo